In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Cramer shares his views on how much further Citigroup and Goldman Sachs have to run and cautions that you can't wait for everyone to love a stock.
The worst appears to be over for this sector; we could see big growth ahead.
Based on the negative study results, Lilly will not pursue regulatory approvals for solanezumab in Alzheimer's disease.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.